Ivan Cohen-Tanugi, a biologics expert, has been appointed chief executive of Eyevensys SAS which is developing a gene therapy for ocular diseases. Dr Cohen-Tanugi was previously vice president and general manager of the biologics and specialty unit at Teva Pharmaceuticals in the US. He has also worked for the pharmaceutical division of Roche and for Amgen Inc. He is a medical doctor and also holds an MBA from the HEC Business School in Paris.
Eyevensys announced the appointment on 25 March 2013.
Copyright 2013 Evernow Publishing Ltd.